Literature DB >> 23485997

Expression of Rac1, HIF-1α, and VEGF in gastric carcinoma: correlation with angiogenesis and prognosis.

Hongjie Zhan1, Han Liang, Xiangyu Liu, Jingyu Deng, Baogui Wang, Xishan Hao.   

Abstract

BACKGROUND: The aim of this study was to investigate the relationship between the expression of hypoxia-inducible factor-1α (HIF-1α), Ras-related C3 botulinum toxin substrate 1 (Rac1), and vascular endothelial growth factor (VEGF), as well as their correlation with angiogenesis and prognosis in gastric carcinoma.
MATERIAL AND METHODS: The expression of Rac1, HIF-1α, VEGF, and CD34 (described in terms of microvessel density, MVD) was determined by immunohistochemical staining of tissues from 60 radically resected gastric cancer specimens.
RESULTS: The proportion of specimens expressing Rac1, HIF-1α, and VEGF was 37/60 (61.7%), 35/60 (58.3%), and 40/60 (66.7%), respectively. The levels of Rac1, HIF-1α, and VEGF expression were significantly correlated with Lauren's classification, lymph node metastasis, and pathologic staging (p < 0.05). There were positive correlations between MVD and the expression of Rac1, HIF-1α, and VEGF. The mean survival time and 5-year survival rate in cases with positive Rac1, HIF-1α, and VEGF expression and MVD ≥ 26.3 were significantly shorter than those with negative Rac1, HIF-1α, and VEGF expression and MVD < 26.3.
CONCLUSION: Rac1, HIF-1α, and VEGF play an important role in tumor invasion and metastasis, especially in tumor angiogenesis. Thus, testing the expression of Rac1, HIF-1α, and VEGF may be a useful index for treatment and prognosis.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23485997     DOI: 10.1159/000348525

Source DB:  PubMed          Journal:  Onkologie        ISSN: 0378-584X


  8 in total

1.  Expression of cluster of differentiation 34 and vascular endothelial growth factor in breast cancer, and their prognostic significance.

Authors:  Zhanhong Chen; Shenhua Xu; Weizhen Xu; Jian Huang; G U Zhang; Lei Lei; Xiying Shao; Xiaojia Wang
Journal:  Oncol Lett       Date:  2015-06-10       Impact factor: 2.967

Review 2.  Meta-analysis of immunohistochemical expression of hypoxia inducible factor-1α as a prognostic role in gastric cancer.

Authors:  Shuang Lin; Rui Ma; Xue-Yong Zheng; Hong Yu; Xiao Liang; Hui Lin; Xiu-Jun Cai
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

3.  Down regulation of RNA binding motif, single-stranded interacting protein 3, along with up regulation of nuclear HIF1A correlates with poor prognosis in patients with gastric cancer.

Authors:  Youliang Wu; Dapeng Yun; Yingjie Zhao; Yuqi Wang; Ruochuan Sun; Qiang Yan; Shangxin Zhang; Mingdian Lu; Zhen Zhang; Daru Lu; Yongxiang Li
Journal:  Oncotarget       Date:  2017-01-03

Review 4.  Prognostic and Clinicopathological Value of Rac1 in Cancer Survival: Evidence from a Meta-Analysis.

Authors:  Shu Lou; Penglai Wang; Jianrong Yang; Junqing Ma; Chao Liu; Meng Zhou
Journal:  J Cancer       Date:  2018-06-23       Impact factor: 4.207

5.  sFRP1 exerts effects on gastric cancer cells through GSK3β/Rac1‑mediated restraint of TGFβ/Smad3 signaling.

Authors:  Ji-Xiang Peng; Shun-Yu Liang; Li Li
Journal:  Oncol Rep       Date:  2018-10-31       Impact factor: 3.906

6.  Hypoxia and proangiogenic proteins in human ameloblastoma.

Authors:  Raíssa Pinheiro de Mendonça; Karolyny Martins Balbinot; Beatriz Voss Martins; Maria Sueli da Silva Kataoka; Ricardo Alves Mesquita; João de Jesus Viana Pinheiro; Sérgio de Melo Alves Júnior
Journal:  Sci Rep       Date:  2020-10-16       Impact factor: 4.379

7.  Lipopolysaccharide Effect on Vascular Endothelial Factor and Matrix Metalloproteinases in Leukemic Cell Lines In vitro.

Authors:  Fatemeh Hajighasemi; Mohammad Hossein Gheini
Journal:  Iran J Cancer Prev       Date:  2015-05-22

8.  miR-124-3p acts as a potential marker and suppresses tumor growth in gastric cancer.

Authors:  Feng Liu; Hongjuan Hu; Jianfu Zhao; Zhiwei Zhang; Xiaohong Ai; Liyun Tang; Liming Xie
Journal:  Biomed Rep       Date:  2018-06-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.